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We report for the first time in Brazil, a patient from whom an Enterococcus faecalis VanA
phenotype was isolated. Glycopeptide resistance is not commonly observed in Enterococcus
faecalis, so this finding is of great concern since this species is responsible for 90% of
enterococcal infections in Brazil. The isolate was recovered from a surveillance rectal swab
culture from a patient with acute lymphocytic leukemia (ALL). Identification to the species level
was performed by conventional biochemical tests and Vitek GPI cards. Antimicrobial susceptibility
testing was evaluated by use of broth microdilution and Etest (AB BIODISK, Solna, Sweden)
methods. The isolate was identified as E. faecalis and was considered resistant to both vancomycin
(MIC, > 256 µg/mL) and teicoplanin (MIC, 256 µg/mL). The isolate also showed high level
resistance to gentamicin and streptomycin (MICs, > 1024 µg/mL), but was considered susceptible
to ampicillin (MIC, 4 µg/mL). Although the frequency of enterococcal infections is very low in
most Latin America countries, the finding of glycopeptide (VanA) resistance in E. faecalis increases
concern about apreading antimicrobial resistance in this region.
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Glycopeptide-resistant enterococci, best known as
vancomycin-resistant enterococci (VRE), have
emerged as an important human pathogen responsible
for serious systemic infections, especially in debilitated
hosts with lowered defense mechanisms [1]. The
problem is complicated by the inherent drug resistance
of this pathogen. Enterococcus faecalis, the most
commonly occurring species in this genus, has acquired
high-level aminoglycoside resistance, and
glycopeptide resistance, although ampicillin resistance
is still rarely found.
E. faecium, the second most frequent enterococcal
species, is inherently more resistant to many
antimicrobial agents. In Brazil, approximately one half
of clinical E. faecium isolates are resistant to ampicillin.
In addition, high-level aminoglycoside resistance and
glycopeptide resistance are usually much higher among
this species when compared to E. faecalis [2].
Three different genotypes have been described in
E. faecium and E. faecalis: vanA, vanB, and vanD.
These genes encode either high-, intermediate-, or low-
level resistance to glycopeptides. In addition of these
genotypes, VRE is categorized in two general
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phenotypes: 1) VanA or Class A – high level resistance
to vancomycin and teicoplanin; and 2) VanB or Class
B – the isolates are resistant to vancomycin but remain
susceptible to teicoplanin (MIC, < 8 µg/mL). Although
E. faecalis is by far the most frequently isolated
enterococcal species, VanA phenotype is rarely found
in this species. A fourth genotype, vanC, is intrinsic
for E. gallinarum and E. casseliflavus, and encodes
resistance to vancomycin (low-level) but not to
teicoplanin [3, 4].
The main source or reservoir of VRE remains unclear,
but the acquisition of the strain may follow previous
colonization of the patient (endogenous acquisition) or
it may be acquired from other patients (exogenous
acquisition) [3, 4]. The acquisition of VRE via the food
chain has been proposed in some studies, since vanA
E. faecium has been isolated from farm animals and
from animal-derived food products [5, 6]. The
gastrointestinal tract is considered an important reservoir
from which dissemination of resistant strains of
enterococci may occur [7]. Nosocomial outbreaks have
been associated with gastrointestinal colonization by VRE
in patients with prolonged hospitalization and prolonged
use of broad-spectrum antimicrobial agents [8].
Once VRE becomes established in a clinical unit or
medial center, it may cause a range of infections
associated with high mortality. Moreover, there is a
potential for glycopeptide resistance genes to spread
to other, more virulent organisms [3]. Since there is no
widely accepted therapy for infections due to
multiresistant VRE, it is essential to limit the spread of
these microorganisms.
Although a few cases of infections due to
vancomycin-resistant E. faecium have recently been
described in Brazil [9], this is the first case involving an
E. faecalis strain.
Case Report
A 23-year-old woman with acute lymphocytic
leukemia (ALL) was hospitalized at the São Paulo
Hospital (Federal University of São Paulo, São Paulo,
Brazil) in December, 1997. She had several previous
hospitalizations and antimicrobial treatment with
glycopeptides, cephalosporins, carbapenem, and
fluoroquinolones. On January 9, 1998, after receiving
acyclovir, gancyclovir, fluconazole, cotrimoxazole,
enduxan, and methotrexate for 7 days, she received a
bone marrow transplant. A Hickman catheter was
placed for drug administration. In addition, the patient
had a catheter placed for bladder irrigation for 3 days.
No other device was used during hospitalization. On
January 12, the patient had an elevated temperature
and mucositis. Because of the fever, ceftazidime and
amikacin were initiated. After 24 hours, the amikacin
was replaced with vancomycin and meropenem. Four
days later, the patient was still febrile and the mucositis
was grade III in intensity. Amphotericin B was introduced
at this time. After 5 days, the patient became afebrile
and asymptomatic. On January 30, the patient’s white
cell count was 900/mm3 and all antimicrobial agents were
withdrawn. Four days later she was discharged.
A surveillance rectal swab culture collected on
January 14, grew E. faecalis. The swab was plated
on a blood agar screen plate containing vancomycin
6 µg/mL, aztreonam 60 µg/mL, and nystatin 12.5 µg/
mL. After incubation at 37 °C for 24 hours, Gram’s
stain was performed and Gram-positive cocci were
detected and subcultured on non-selective sheep
blood agar.  Identification to the species level was
performed by conventional methods proposed by
Fackland and Collins [10]. Vancomycin, teicoplanin,
ampicillin, gentamicin, and streptomycin sensitivity
were evaluated by the Etest (AB BIODISK, Solna,
Sweden) method [11]. The MIC results were as
follows: vancomycin > 256 µg/mL (resistant),
teicoplanin 256 µg/mL (resistant), ampicillin 4 µg/mL
(susceptible), gentamicin and streptomycin > 1,024
µg/mL (high-level resistance). The results for other
antimicrobial agents are shown as in Table 1. A double
zone of inhibition was observed for vancomycin and
teicoplanin. The strain was sent to the University of
Iowa (Iowa City, IA, USA) for further
characterization. Local results were confirmed and
the same double zone phenomenon was observed.
In addition, the strain demonstrated a double zone
for ampicillin (Table 2). Colonies in the Etest double
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zones (DZ) of ampicillin, teicoplanin, and vancomycin
were collected and tested separately. Two of 3 DZ
isolates demonstrated identical susceptibility testing
results by Etest, but the isolate subcultured from the
DZ on the ampicillin strip (isolate number 3) was
susceptible to both vancomycin and teicoplanin
(Table 2). The pulsed-field gel electrophoresis
(PFGE – Figure 1)[12] and ribotype (Riboprinter,
E. I. duPont the Nemours, Wilmington, DE, USA)
[13] were identical for all 3 isolates and the original
strain, and the vanA gene was identified in the
original strain and both DZ isolates with the VanA
phenotype (vancomycin DZ isolate and teicoplanin
DZ isolate). Additional PCR tests [14] confirmed
high-level gentamicin resistance and the species
identifications, e.g. E. faecalis (Table 2). A plasmid
analysis was performed and the vanA samples
presented an identical profile (Figure 2) [15]. In spite
of repeating the test several times and using different
enzymes, we were not able to evaluate the
plasmid analysis on isolate number 3 (ampicillin
DZ isolate).
Discussion
Enterococcal infections can be associated with
significant morbidity and mortality because they
often occur in critically ill patients, especially those
receiving organ transplants [1, 3]. If the strain
reported here had caused a systemic infection, the
treatment would have been very difficult. Isolates
with high-level resistance to aminoglycosides are
refractory to the synergistic effects that occur when
these compounds are associated with cell-wall
active drugs, such as β-lactams and glycopeptides.
Multiple risk factors are related to infection by VRE,
and colonization (like the case reported here)
usually precedes the infection [16]. VRE carriage
Table 1. Antimicrobial susceptibility pattern of the original strain evaluated by Etest and broth microdilution
methods
Enterococcus faecalis Resistant to Vancomycin and Teicoplanin
Antimicrobial agents MIC (mg/mL)
Etest Broth microdilution
Ampicillin 4 4
Cefazolin - > 16
Cefotaxime - > 32
Ciprofloxacin - > 2
Clindamycin - > 16
Chloramphenicol - > 16
Doxycycline - 8
Erythromycin - > 16
Gentamicin >1024 > 500
Imipenem > 32 -
Levofloxacin > 32 -
Meropenem > 32 -
Oxacillin - > 8
Penicillin > 32 -
Quinupristin/dalfopristin - > 16
Streptomycin >1024 -
Teicoplanin > 256 -
Vancomycin > 256 -
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Table 2. Characterization of the samples by Etest, Ribotype, PCR and Vitek GPI
Test Original Straina Isolate (1) b Isolate (2) b Isolate (3) b
Etest (µg/mL) Vancomycin > 256 (2)c > 256 > 256 (2) c 1.5
Teicoplanin 64 (0.25) c > 256 (0.25) c > 256 0.38
Ampicillin 4 (1) c 4 4 4
Streptomycin 96 512 256 256
Gentamicin > 2048 > 2048 > 2048 > 2048
Ribotype 723-3 723-3 723-3 723-3
PCR van gene vanA vanA vanA van neg
High-level streptomycin resistance negative negative negative negative
High-level gentamicin resistance positive positive positive positive
Species E. faecalis E. faecalis E. faecalis E. faecalis
E. faecalis GPI Identification E. faecalis E. faecalis E. faecalis E. faecalis
Profile # 77767630610 77767630610 77767630610 77767630610
a
 Original strain;
b
 Subcultures from Etest double zone (DZ) colonies:
(1) = vancomycin strip (DZ vancomycin),
(2) = teicoplanin strip (DZ teicoplanin),
(3) = ampicillin strip (DZ ampicillin).
c
 MIC results when reading the internal zone are in parenthesies.
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Figure 1. Pulsed field gel electrophoresis (PFGE) of chromosomal DNA digested with SmaI. Column 1: original
strain; column 2: isolate from the ampicillin double zone; column 3: isolate from the teicoplanin double zone;
column 4 vancomycin double zone
Figure 2. Electrophoresis of plasmid DNA digested with HindIII and EcoR1. Column 1: original strain; column
2: isolate from the ampicillin double zone; column 3: isolate from the teicoplanin double zone; column 4 vancomy-
cin double zone; columns 5 and 6: susceptible controls
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tends to be prolonged (from 19 to 303 days), and
a patient whose gastrointestinal tract is colonized
with VRE may function as a reservoir and facilitate
the nosocomial dissemination of this pathogen. In
addition, these patients will have a sustained risk
for developing VRE infection [7, 17].
Over the last 3 years, our prospective VRE
surveillance program has not identified any glycopeptide
resistant strain [18]. Rectal swabs are obtained twice
weekly from all ICU patients. The swab is plated on a
selective agar screen plate. A total of 516 rectal swabs
were cultured during a 17-month period and 37
vancomycin-intermediate enterococci isolates (MIC,
16 µg/mL) were recovered from 11 patients (1.2%).
These isolates were identified as E. gallinarum (28
isolates), E. casseliflavus (5 isolates), E. faecalis (3
isolates), and E. faecium (1 isolate). vanA, vanB or
vanC genes were not identified among E. faecalis or
E. faecium strains. Although our medical center has
several important risk factors for the appearance of
VRE (600-bed university hospital, vancomycin use of
245 defined daily dose/1000 bed-days in the intensive
care unit), this is the first glycopeptide-resistant E.
faecalis strain identified.
Despite the fact that one isolate had a distinct
vancomycin susceptibility pattern by Etest, the PFGE
and ribotyping results of all isolates analyzed were
identical. The hypothesis of mixed culture was excluded
because all isolates had identical PFGE and ribotyping
patterns (Figure 1). However, as previously observed
by Woodford, et al. [19], PFGE analysis and the
resistance phenotype may not be sufficient to accurately
define the epidemiology of enterococci. These results
reinforce the difficulties found in the characterization of
VRE isolates. The fact that one of these isolates
separated from the Etest double zones (the ampicillin
DZ isolate) had a vancomycin MIC distinct from the
other isolates with identical chromosomal patterns, may
be explained by the loss of the plasmid containing vanA
gene, since we could not detect plasmid in this
vancomycin-susceptible isolate.
The detection of the present case, as well as other
cases of colonization/infection due to VRE in Brazil,
warns us of for the very recent appearance and
dissemination of this important cause of nosocomial
infections in our environment. A surveillance program
is necessary to rapidly detect and control the
appearance and dissemination of VRE on a nation-
wide basis. The microbiology laboratories have an
important role as the first line of defense by detecting
these resistant strains accurately and quickly.
Measures for preventing the spread of VRE in
hospitals include the application of strict isolation
precautions and the implementation of effective
antimicrobial use control programs.
In summary, the clinical laboratories in Brazil must
be prepared to detect VRE, and infection control
personnel should be prepared to contain potential
outbreaks before the pathogen becomes endemic.
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